Losartan can be effective for African American patients, but it works best as part of combination therapy rather than on its own. As a standalone medication, losartan produces more modest blood pressure reductions in Black patients compared to other groups, and one major clinical trial raised concerns about cardiovascular outcomes. However, when paired with a diuretic or calcium channel blocker, losartan becomes a valuable tool, especially for Black patients who also have diabetes or kidney disease.
How Losartan Performs as a Solo Medication
Losartan belongs to a class of drugs called ARBs (angiotensin receptor blockers), which work by blocking a hormone that tightens blood vessels. In a clinical trial of Black adults with mild to moderate high blood pressure, losartan monotherapy lowered systolic blood pressure by about 6.4 mmHg and diastolic blood pressure by 6.6 mmHg over 12 weeks. The response rate was 45.8%, meaning fewer than half the participants hit their blood pressure target on losartan alone.
Those reductions are real but relatively modest. By comparison, thiazide diuretics (water pills) and calcium channel blockers tend to produce larger blood pressure drops in Black patients when used alone. This is why guidelines from the ACC/AHA have long recommended thiazide-type diuretics as first-line therapy, and why many doctors start with those medications or calcium channel blockers for Black patients who don’t have other conditions pointing toward a different choice.
Why ARBs Work Differently in Black Patients
The explanation comes down to how the body regulates blood pressure. Losartan targets something called the renin-angiotensin system, a hormonal pathway that controls blood vessel tightness and fluid balance. Black patients with high blood pressure tend to have lower levels of circulating renin, which is the enzyme that kicks off this pathway. With less renin activity in the bloodstream, blocking the pathway with an ARB produces a smaller blood pressure response.
The biology is more complex than it first appears, though. Research in salt-sensitive models of hypertension has shown that even when renin levels are low in the bloodstream, renin activity inside the kidneys and blood vessel walls can be elevated. Blocking this tissue-level activity with an ARB reversed blood vessel dysfunction, reduced protein in the urine (a sign of kidney damage), and lowered heart and kidney injury, even without fully normalizing blood pressure. This suggests losartan may offer protective benefits for the kidneys and heart that go beyond its blood pressure number on a monitor.
The LIFE Study: A Key Concern
The most important cautionary data comes from the LIFE trial, a large study comparing losartan-based therapy to atenolol-based therapy (a beta-blocker) in over 9,000 patients with high blood pressure and an enlarged heart. In the overall study population, losartan came out ahead: fewer strokes, fewer cardiovascular events. But when researchers looked specifically at the 533 Black patients in the trial, the results flipped.
Black patients on losartan-based therapy had a 67% higher rate of the combined endpoint of cardiovascular death, stroke, and heart attack compared to those on atenolol. The increase was driven largely by more strokes in the losartan group. Notably, blood pressure reductions were similar between the two treatment arms in Black patients, so the difference in outcomes wasn’t explained by one group having higher blood pressure. The study authors concluded that these results “do not support a recommendation for losartan as a first-line treatment” in Black patients with hypertension and enlarged hearts.
This was a subgroup analysis of a relatively small number of Black participants, so it generates a hypothesis more than it proves a rule. Still, it’s a finding that has shaped how doctors think about prescribing losartan as monotherapy in this population.
Where Losartan Fits: Combination Therapy
The picture changes substantially when losartan is combined with other medications. Adding a low-dose thiazide diuretic like hydrochlorothiazide to losartan produces significantly greater blood pressure reductions in Black patients than using losartan alone. A study of 440 Black American adults confirmed the effectiveness of this specific combination for mild to moderate hypertension.
The International Society of Hypertension in Blacks recommends combination therapy with an ARB and a calcium channel blocker as a first-line approach. This pairing addresses the salt-sensitive, volume-dependent pattern of hypertension more common in Black patients (through the calcium channel blocker) while also blocking the renin-angiotensin system (through the ARB). The result is better blood pressure control than either drug alone.
Combination therapy matters especially for Black patients with diabetes or chronic kidney disease, conditions that disproportionately affect this population. Drugs that block the renin-angiotensin system, including losartan, slow the progression of kidney damage in diabetic patients. Since kidney protection is a priority for many Black patients with hypertension, an ARB combined with a diuretic or calcium channel blocker can address both blood pressure and organ protection simultaneously.
Losartan vs. ACE Inhibitors for Black Patients
ACE inhibitors (like lisinopril and enalapril) target the same hormonal pathway as losartan but at a different point. For Black patients specifically, losartan and other ARBs hold one clear advantage: a much lower risk of angioedema, a potentially dangerous swelling of the face, throat, and airway.
Black patients have roughly 4.5 times the risk of ACE inhibitor-related angioedema compared to white patients. This elevated risk persists regardless of dose, specific ACE inhibitor used, or other medications taken at the same time. ARBs like losartan cause angioedema far less frequently, making them the preferred option when a renin-angiotensin system blocker is needed. The ISHIB guidelines specifically note that ARBs are a better choice than ACE inhibitors for Black patients for this reason.
The ALLHAT trial reinforced the concern about ACE inhibitors: Black patients randomized to lisinopril had higher rates of heart failure, stroke, and overall cardiovascular events compared to those taking the diuretic chlorthalidone, along with about 4 mmHg less systolic blood pressure reduction.
What This Means in Practice
If you’re a Black patient taking losartan alone and your blood pressure isn’t reaching target, that’s a common and expected pattern. The fix isn’t necessarily switching away from losartan. Adding a thiazide diuretic or calcium channel blocker often brings blood pressure into range while preserving losartan’s kidney-protective benefits.
If you don’t have diabetes or kidney disease and your doctor is choosing a first medication for high blood pressure, a thiazide diuretic or calcium channel blocker alone is the most evidence-supported starting point. Losartan typically enters the picture as a second agent or when there’s a specific reason to protect the kidneys.
The standard starting dose of losartan is 50 mg once daily, with adjustments based on your blood pressure response. For Black patients, the expectation should be that combination therapy will likely be needed. That’s not a failure of the medication. It reflects how blood pressure regulation works differently across populations, and modern guidelines account for it.